FDA Warns of Risk for PE, Death With Higher Dose Xeljanz - Medscape

FDA Warns of Risk for PE, Death With Higher Dose Xeljanz  Medscape

The FDA is warning of an increased risk for pulmonary embolism and death in patients with rheumatoid arthritis who received tofacitinib (Xeljanz, Xeljanz XR) 10 ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more